January 2026 Research Update

This month brought early, but very different, signals about ways researchers are trying to address the weight gain and blood-sugar problems that are common in Alstrom syndrome. One report in a child suggested that dulaglutide (a GLP-1 receptor agonist, a medicine used for blood sugar and weight in other conditions) was followed by improved body-size measures and improved long-term blood sugar over time. Separately, a mouse study tested a new antibody approach that changed weight gain and metabolic features in an Alstrom-related model, which is encouraging for research but not yet a human result. [1] [2]

In the single-child report, dulaglutide was used over 48 weeks and the child had a drop in BMI percentile measures and a 1.2 percentage point decrease in HbA1c (a lab test that reflects average blood sugar over about 3 months). Because this is one patient without a comparison group, it cannot show what would happen for most people, but it adds a concrete example of how a GLP-1 medicine might perform in Alstrom syndrome when followed over many months. [1]

In mice with ALMS1 deficiency, researchers reported early liver changes related to fat handling and higher levels of ACBP, a protein involved in metabolism. When they gave an antibody that neutralizes extracellular ACBP, the mice had less weight gain and many measured metabolic and gut microbiome changes moved back toward the non-Alstrom pattern. This is lab and animal research, so it mainly helps identify possible targets and does not tell us whether the same approach would be safe or helpful in people with Alstrom syndrome. [2]

For patients and caregivers, the main point is that Januarys studies added early evidence in 2 directions: a real-world, single-person experience with dulaglutide, and a separate animal-based approach aimed at a specific metabolic signal (ACBP). The dulaglutide case may matter now as a starting point for future studies, but by itself it cannot predict who might benefit or what side effects might appear in broader use. The antibody work mainly matters for the future, because it is still at the stage of testing a concept in mice and mapping out biology that could guide new therapies. [1] [2]

This month also highlighted that living with Alstrom syndrome can look different depending on access to testing and specialty care, while the condition still affects multiple organs in recognizable patterns. A case report from a resource-limited setting described a clinical (non-genetic) diagnosis and a coordinated evaluation that captured vision and hearing changes, heart involvement, and metabolic and kidney issues. The short follow-up showed some movement in blood sugar measures, while sensory problems remained unchanged, illustrating how some features may be more modifiable than others over a short time window. [3]

In this single adult patient, genetic testing was not available, so diagnosis relied on established clinical criteria plus examinations and imaging. The report described cone-rod dystrophy (a vision condition affecting light-sensing cells), progressive hearing loss, and heart muscle problems alongside diabetes, abnormal blood fats, obesity, and chronic kidney disease. At 2 months, fasting glucose improved to about 150-170 mg/dL, while vision and hearing deficits were unchanged and kidney function was reported as stable. [3]

For patients, this report mainly adds understanding about how diagnosis can still be made when genetic testing is not accessible, and how Alstrom syndrome often requires looking at several body systems together. It does not establish which treatments work best, because it describes only one person and only a short follow-up period. It may matter now by reflecting real-world barriers and the kinds of problems that can be tracked over time, but its strongest value is descriptive rather than proving cause-and-effect. [3]